Report Sections

See All Reports

  • HP:0005521: Disseminated intravascular coagulation
  • Pneumonia (312) Abnormality of the cardiovascular system (29) Neoplasm (27) Respiratory tract infection (27) Hypoxemia (22) Depressivity (21) Diabetes mellitus (19) Acute kidney injury (19) Abnormal lung morphology (19) Thromboembolism (17) Hypertension (16) Anosmia (14) Myocardial infarction (14) Abnormality of coagulation (14) Stroke (13) Pulmonary embolism (13) Arthritis (12) Leukemia (12) Interstitial pneumonitis (12) Autistic behavior (11) Mental deterioration (11) Deep venous thrombosis (10) Type II diabetes mellitus (10) Pulmonary obstruction (10) Crohn's disease (10) Abnormality of the kidney (9) Autism (9) Obesity (9) Congestive heart failure (9) Chronic pulmonary obstruction (9) Chronic pain (9) Rheumatoid arthritis (8) Abnormality of the liver (8) Respiratory distress (8) Pulmonary fibrosis (8) Colitis (8) Myocarditis (8) Carcinoma (8) Ulcerative colitis (8) Behavioral abnormality (7) Dementia (7) Infertility (7) Inflammation of the large intestine (7) Pulmonary insufficiency (7) Low levels of vitamin D (7) Neoplasm of the lung (7) Type I diabetes mellitus (7) Psychosis (6) Coronary artery atherosclerosis (6) Lymphoma (6) Abnormality of the gastrointestinal tract (6) Chronic kidney disease (6) Sepsis (6) Renal insufficiency (5) Lymphopenia (5) Gastroparesis (5) Immunodeficiency (5) Systemic lupus erythematosus (5) Breast carcinoma (5) Peripheral arterial stenosis (5) Allergy (5) Encephalopathy (4) Hepatic fibrosis (4) Cardiac arrest (4) Dysphagia (4) Asthma (4) Alzheimer disease (4) Osteoarthritis (4) Neoplasm of the pancreas (4) Autoimmunity (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Sleep apnea (4) Prostate cancer (4) Neoplasm of head and neck (4) Addictive behavior (4) Insomnia (4) Obsessive-compulsive behavior (3) Seizure (3) Cardiomyopathy (3) Weight loss (3) Fever (3) Migraine (3) Pulmonary arterial hypertension (3) Bronchiectasis (3) Obstructive sleep apnea (3) Colon cancer (3) Reduced factor VIII activity (3) Malnutrition (3) Knee osteoarthritis (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Arrhythmia (3) Fatigue (3) Endometriosis (3) Non-small cell lung carcinoma (3) Neuroendocrine neoplasm (3) Hypercoagulability (3) Schizophrenia (3) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormal heart morphology (2) Tachycardia (2) Angina pectoris (2) Gastroesophageal reflux (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Mutism (2) Headache (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Atherosclerosis (2) Hypoventilation (2) Myelodysplasia (2) Psoriasiform dermatitis (2) Paroxysmal atrial fibrillation (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Cystoid macular edema (2) Hemeralopia (2) Cutaneous melanoma (2) Arteritis (2) Glioblastoma multiforme (2) Cervix cancer (2) Pulmonary edema (2) Ovarian neoplasm (2) Angioedema (2) Mania (2) Neoplasm of the large intestine (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Hypogeusia (1) Conductive hearing impairment (1) Abnormality of the eye (1) Cataract (1) Amblyopia (1) Periodontitis (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Abnormality of the skin (1) Jaundice (1) Lymphedema (1) Angiokeratoma corporis diffusum (1) Keratoconjunctivitis (1) Spasticity (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic steatosis (1) Hepatic failure (1) Hepatocellular carcinoma (1) Premature birth (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Pancreatitis (1) Abnormality of blood and blood-forming tissues (1) Gout (1) Diarrhea (1) Anorexia (1) Esophageal varix (1) Hypothermia (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Encephalitis (1) Waddling gait (1) Increased intracranial pressure (1) Celiac disease (1) Biliary cirrhosis (1) Hypotension (1) Osteomyelitis (1) Squamous cell carcinoma (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Back pain (1) Low back pain (1) Muscular dystrophy (1) Neonatal death (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Coronary artery stenosis (1) Chronic lymphatic leukemia (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Abnormal anterior horn cell morphology (1) Amyotrophic lateral sclerosis (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Inflammatory abnormality of the skin (1) Sinus tachycardia (1) Bronchiolitis (1) Postprandial hyperglycemia (1) Hepatitis (1) Erythroid hypoplasia (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Small cell lung carcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Subdural hemorrhage (1) Endocarditis (1) Toxemia of pregnancy (1) Myositis (1) Vaginal neoplasm (1) Cellulitis (1) Self-injurious behavior (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0005521: Disseminated intravascular coagulation

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (12)


    Name (Synonyms) Correlation
    drug731 Cardiac surgery Wiki 0.50
    drug3471 Thrombin Generation Assay (TGA) Wiki 0.50
    drug1313 Fibrin generation markers assays Wiki 0.50
    Name (Synonyms) Correlation
    drug3472 Thrombin generation test assay Wiki 0.50
    drug3473 Thrombomodulin Modified Thrombin Generation Assay (TGA-TM) Wiki 0.50
    drug2736 Quantra System Wiki 0.50
    drug309 Aspirin 81 mg Wiki 0.50
    drug689 CT-Scan Wiki 0.35
    drug717 Camostat Mesilate Wiki 0.19
    drug3676 Vitamin D Wiki 0.18
    drug1520 Hydroxychloroquine Wiki 0.05
    drug2505 Placebo Wiki 0.02

    Correlated MeSH Terms (7)


    Name (Synonyms) Correlation
    D004211 Disseminated Intravascular Coagulation NIH 1.00
    D020141 Hemostatic Disorders NIH 0.40
    D001778 Blood Coagulation Disorders NIH 0.40
    Name (Synonyms) Correlation
    D014808 Vitamin D Deficiency NIH 0.18
    D016638 Critical Illness NIH 0.06
    D014777 Virus Diseases NIH 0.05
    D007239 Infection NIH 0.02

    Correlated HPO Terms (2)


    Name (Synonyms) Correlation
    HP:0001928 Abnormality of coagulation HPO 0.40
    HP:0100512 Low levels of vitamin D HPO 0.19

    Clinical Trials

    Navigate: Correlations   HPO

    There are 4 clinical trials


    1 Coagulation Assays in the Critically Ill Patient: a New Approach Using the Thrombomodulin-modified Thrombin Generation Assay (TGA-TM)

    Inflammation and abnormalities in laboratory coagulation tests are inseparably tied. For example, coagulation abnormalities are nearly universal in septic patients. Coagulation disorders have also been reported in many patients with severe courses of Coronavirus disease 2019 (Covid-19). But it is difficult to assess these changes. Global coagulation tests have been shown to incorrectly assess in vivo coagulation in patients admitted to intensive care units. But other tests are available. Thrombin generation assay (TGA) is a laboratory test which allows the assessment of an individual's potential to generate thrombin. But also in conventional TGA the protein C system is hardly activated because of the absence of endothelial cells (containing natural thrombomodulin) in the plasma sample. Therefore the investigators add recombinant human thrombomodulin to a conventional TGA. Thereby the investigators hope to be able to depict in vivo coagulation more closely than global coagulation tests do.

    NCT04356144
    Conditions
    1. Disseminated Intravascular Coagulation
    2. Critical Illness
    3. Sars-CoV2
    4. Viral Infection
    5. Coagulation Disorder, Blood
    6. Covid19
    Interventions
    1. Diagnostic Test: Thrombin Generation Assay (TGA)
    2. Diagnostic Test: Thrombomodulin Modified Thrombin Generation Assay (TGA-TM)
    MeSH:Infection Virus Diseases Hemostatic Disorders Blood Coagulation Disorders Disseminated Intravascular Coagulation Critical Illness
    HPO:Abnormality of coagulation Abnormality of the coagulation cascade Disseminated intravascular coagulation

    Primary Outcomes

    Description: nM;

    Measure: ETP (AUC) without rhThrombomodulin (rhTM)

    Time: 6 months

    Description: nM;

    Measure: ETP (AUC) with rhThrombomodulin (rhTM)

    Time: 6 months

    Description: Ratio of endogenous thrombin potential (ETP) with rhTM to ETP without rhTM

    Measure: ETP-ratio

    Time: 6 months

    Description: Comparison of ETP-ratios from ICU patients and ETP-ratios from citrated plasma samples from healthy donors

    Measure: ETP-Normalisation

    Time: 6 months
    2 Analysis of the Coagulopathy Developed by COVID-19 Infected Patients: Thrombin Generation Potential in COVID-19 Infected Patients

    Increased D-dimers at admission of COVID-19 infected patients entering hospital due to a severe disease is a risk factor for death. Understanding this acquired coagulopathy is a prerequisite before specific interventional studies. The study investigators aim to apply a normalized and automated thrombin generation test (TGT), developed for testing the thrombotic risk (triggered by 5 pM Tissue Factor, with a purified thrombomodulin (TM) challenge) and to study its association with survival.

    NCT04356950
    Conditions
    1. Sepsis
    2. Blood Coagulation Disorders
    3. Thrombin
    4. Disseminated Intravascular Coagulation
    5. COVID-19
    Interventions
    1. Other: Thrombin generation test assay
    2. Other: Fibrin generation markers assays
    MeSH:Hemostatic Disorders Blood Coagulation Disorders Disseminated Intravascular Coagulation
    HPO:Abnormality of coagulation Abnormality of the coagulation cascade Disseminated intravascular coagulation

    Primary Outcomes

    Description: Death yes/no during hopstilization, 28 days after admittence

    Measure: 28-day survival rate

    Time: 1 month

    Description: Seconds; without (TM-) and with (TM+) purified thrombomodulin

    Measure: Absolute thrombin generation test latent period

    Time: Day 0

    Description: %; without (TM-) and with (TM+) purified thrombomodulin

    Measure: Relative thrombin generation test latent period compared to reference plasma

    Time: Day 0

    Description: nmol/s; without (TM-) and with (TM+) purified thrombomodulin

    Measure: Absolute thrombin generation test initial velocity

    Time: Day 0

    Description: %; without (TM-) and with (TM+) purified thrombomodulin

    Measure: Relative thrombin generation test initial velocity compared to reference plasma

    Time: Day 0

    Description: %; without (TM-) and with (TM+) purified thrombomodulin

    Measure: Relative thrombin generation test peak thrombin compared to reference plasma

    Time: Day 0

    Description: nmol/L; without (TM-) and with (TM+) purified thrombomodulin

    Measure: Absolute thrombin generation test peak thrombin

    Time: Day 0

    Description: Seconds; without (TM-) and with (TM+) purified thrombomodulin

    Measure: Absolute thrombin generation test peak thrombin time

    Time: Day 0

    Description: %; without (TM-) and with (TM+) purified thrombomodulin

    Measure: Relative thrombin generation test peak thrombin time compared to reference plasma

    Time: Day 0

    Description: seconds; without (TM-) and with (TM+) purified thrombomodulin

    Measure: Absolute thrombin generation test total thrombin generation time

    Time: Day 0

    Description: %; without (TM-) and with (TM+) purified thrombomodulin

    Measure: Relative thrombin generation test total thrombin generation time compared to reference plasma

    Time: Day 0

    Description: Seconds; without (TM-) and with (TM+) purified thrombomodulin

    Measure: Absolute thrombin generation test endogenous thrombin potential

    Time: Day 0

    Description: %; without (TM-) and with (TM+) purified thrombomodulin

    Measure: Relative thrombin generation test endogenous thrombin potential compared to reference plasma

    Time: Day 0

    Secondary Outcomes

    Description: Death yes/no

    Measure: 3-month survival rate

    Time: 3 months

    Description: Yes/no

    Measure: Transfer to intensive care unit during hospitalization

    Time: 3 months

    Description: Yes/no (deep vein thrombosis, pulmonary embolism, atherothrombosis flare, arterial thrombosis)

    Measure: Thrombotic complication during hospitalization

    Time: 3 months

    Description: µg / L, assayed by automated enzyme linked fluorescent assay (Vidas® D-dimers Exclusion ™ II)

    Measure: Plasma concentrations of D-dimers

    Time: Day 0

    Description: mg / L, measured by automated immunoagglutination (STA®-Liatest® FM)

    Measure: Plasma concentrations of soluble fibrin monomers

    Time: Day 0
    3 The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations

    Although the novel SARS-CoV-2 virus (COVD-19) is classified as an acute respiratory infection, emerging data show that morbidity and mortality are driven by disseminated intravascular coagulopathy. Untreated CAC leads to microangiopathic thromboses, causing multiple systems organ failure and consuming enormous healthcare resources. Identifying strategies to prevent CAC are therefore crucial to reducing COVID-19 hospitalization rates. The pathogenesis of CAC is unknown, but there are major overlaps between severe COVID-19 and vitamin D insufficiency (VDI). We hypothesize that VDI is a major underlying contributor to CAC. Preliminary data from severe COVID-19 patients in New Orleans support this hypothesis. The purpose of the proposed multi-center, prospective, randomized controlled trial is to test the hypothesis that low-risk, early treatment with aspirin and vitamin D in COVID-19 can mitigate the prothrombotic state and reduce hospitalization rates.

    NCT04363840
    Conditions
    1. COVID
    2. Vitamin D Deficiency
    3. Coagulopathy
    4. Disseminated Intravascular Coagulation
    Interventions
    1. Drug: Aspirin 81 mg
    2. Dietary Supplement: Vitamin D
    MeSH:Disseminated Intravascular Coagulation Vitamin D Deficiency
    HPO:Disseminated intravascular coagulation Low levels of vitamin D

    Primary Outcomes

    Description: Hospitalization for COVID-19 symptoms

    Measure: Hospitalization

    Time: 2 weeks
    4 Exploratory Assessment of the Coagulation Changes Associated With Severe Inflammation in COVID-19 Patients

    This study will study the potential utility of the Quantra QPlus System in patients inflicted with COVID-19 disease.

    NCT04460664
    Conditions
    1. COVID
    2. Disseminated Intravascular Coagulation
    3. Coagulation Disorder
    Interventions
    1. Diagnostic Test: Quantra System
    MeSH:Hemostatic Disorders Blood Coagulation Disorders Disseminated Intravascular Coagulation
    HPO:Abnormality of coagulation Abnormality of the coagulation cascade Disseminated intravascular coagulation

    Primary Outcomes

    Description: Coagulation function assessed by the Quantra

    Measure: Quantra Clot Time results

    Time: Within 24 hours of admission to the hospital

    Description: Coagulation function assessed by the Quantra

    Measure: Quantra Clot Time results

    Time: 48 to 72 hours after transfer to ICU

    Description: Coagulation function assessed by the Quantra

    Measure: Quantra Clot Time results

    Time: 1 to 24 hours prior to discharge from hospital

    Description: Coagulation function assessed by the Quantra

    Measure: Quantra Clot Stiffness results

    Time: Upon arrival at hospital

    Description: Coagulation function assessed by the Quantra

    Measure: Quantra Clot Stiffness results

    Time: 48 to 72 hours after transfer to ICU

    Description: Coagulation function assessed by the Quantra

    Measure: Quantra Clot Stiffness results

    Time: 1 to 24 hours prior to discharge from hospital

    HPO Nodes


    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook